Patents Assigned to Pfizer
  • Publication number: 20030165563
    Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: December 20, 2002
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Brendan Murphy, Steven W. Collier, Ernest Quan, Barbara A. Johnson
  • Publication number: 20030166582
    Abstract: This invention is directed to compounds of the formula (I): 1
    Type: Application
    Filed: November 27, 2002
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Anne E. Hagen, R. Scott Obach
  • Publication number: 20030166662
    Abstract: Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.
    Type: Application
    Filed: February 19, 2003
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: David Albert Fryburg, Earl Michael Gibbs, Nandan Parmanand Koppiker
  • Publication number: 20030166704
    Abstract: The present invention provides an improved process for the preparation of the anti-migraine drug, (R)-5-(2-benzenesulphonylethyl)-3-N-methylpyrrolidin-2-ylmethyl)-1H-indole (eletriptan), available commercially as the hydrobromide salt, and an intermediate and dimer-free products obtained from such process.
    Type: Application
    Filed: November 13, 2001
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventor: Ronald James Ogilvie
  • Publication number: 20030166701
    Abstract: The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.
    Type: Application
    Filed: May 6, 2002
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: David E. Bogle, Peter R. Rose, Glenn R. Williams
  • Publication number: 20030166686
    Abstract: The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating &bgr;3-adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.
    Type: Application
    Filed: February 25, 2003
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Joseph F. Krzyaniak, Jennifer A. Lafontaine
  • Patent number: 6613550
    Abstract: The present invention is directed to a process for the production of compounds of the formula: from a compound of the formula comprising hydroxylating a compound of the formula I in the presence of an enzyme produced by a microorganism of the genera Cunninghamella species or Aspergillus. Preferred microorganisms are Cunninghamella echinulata var. elegans and Aspergillus flavipes. Mixtures of compounds of formulae II and III may also be highly enriched in their composition of compound II by using the enzyme from Cunninghamella echinulata ATC 8688b.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: September 2, 2003
    Assignee: Pfizer Inc.
    Inventor: John W. Wong
  • Patent number: 6613796
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: September 2, 2003
    Assignee: Pfizer Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Publication number: 20030163836
    Abstract: The invention features a transgenic non-human mammal expressing or capable of expressing a GSK-3 transgene comprising a GSK-3 coding sequence, wherein expression of said coding sequence in the mammal is driven by an operably linked regulatory sequence that directs inducible expression in muscle. Following the induction of transgene expression, the transgenic non-human mammal exhibits hyperinsulinemia, increased weight gain on a high fat diet, and/or decreased muscle glycogen content on a high fat, as compared to a control animal not expressing the GSK-3 transgene. The invention also features methods of identifying in vivo modulators of GSK-3 activity.
    Type: Application
    Filed: December 18, 2002
    Publication date: August 28, 2003
    Applicant: Pfizer Inc.
    Inventors: Robert S. Garofalo, Stephen J. Orena, Joel B. Schachter
  • Publication number: 20030162795
    Abstract: The invention relates to compounds of the formulas 1 and 2 1
    Type: Application
    Filed: September 16, 2002
    Publication date: August 28, 2003
    Applicant: Pfizer Inc.
    Inventors: Michael John Munchhof, Susan Beth Sobolov-Jaynes, Matthew Arnold Marx
  • Publication number: 20030162766
    Abstract: The present invention relates to novel aminomethylene substituted non-aromatic heterocycles and, specifically, to compounds of formula (Ia) or (Ib) wherein W, R1, R2, R3, A, X′, Y′ and Z′ are as defined in the specification, and to intermediates used in the syntheses of such compounds. The novel compounds of formulae (Ia) and (Ib) are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Application
    Filed: July 31, 2002
    Publication date: August 28, 2003
    Applicant: Pfizer Inc.
    Inventors: Harry R. Howard, Brian T. O'Neill
  • Publication number: 20030162765
    Abstract: This present invention relates to compounds of the formula 1
    Type: Application
    Filed: February 20, 2003
    Publication date: August 28, 2003
    Applicant: Pfizer Inc.
    Inventors: Robert A. Volkmann, John A. Lowe, Jolanta Nowakowski
  • Patent number: 6610746
    Abstract: The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of:1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: David A. Fryburg, Janice C. Parker
  • Patent number: 6610707
    Abstract: Compounds of the formula: wherein R1, Y, W, A and R2 are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: David John Bull, Robert John Maguire, Michael John Palmer, Martin James Wythes
  • Patent number: 6610847
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Patent number: 6610711
    Abstract: Novel compounds having general formula (I), and pharmaceutically and veterinarily acceptable salts thereof wherein R1, R2, R3, W, Y1, Y2, X, n and y are as defined above and processes for their preparation and intermediate compounds prepared therein. The novel compounds are useful for having utility in the treatment of pruritic dermatoses including allergic dermatitis and atopy in animals and humans.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Richard Edward Armer, Christopher James Dutton, David Morris Gethin, Stephen Paul Gibson, Julian Duncan Smith, Ivan Tommasini
  • Patent number: 6610518
    Abstract: The following invention relates to a process for oxidizing alkyl groups attached directly or via a linker, to a sulfonamide moiety (II) by the use of cytochrome P450 enzymes, to give the corresponding alcohol or carboxylic acid (I). wherein R is an organic radical, X is a linker, Y is —C(CH3)2— or —CH(CH3)— and Z is —CH2OH or —COOH.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: August 26, 2003
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventor: Michael Stephen Pacey
  • Patent number: 6610719
    Abstract: This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Vishwas M. Paralkar, David D. Thompson
  • Patent number: 6610747
    Abstract: A compound of general formula (I) wherein R1 and R2 are H, C1-C6alkyl or (CH2)d(C3-C6cycloalkyl) wherein d=0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is —SR3 and the other Z or Y is halogen or —R3; wherein R3 is C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: A—X, wherein A=—CH═CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(═O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; or a 5- or 6-membered het
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Mavis Diane Adam, Mark David Andrews, Mark Leonard Elliott, Geoffrey Edward Gymer, David Hepworth, Harry Ralph Howard, Jr., Donald Stuart Middleton, Alan Stobie
  • Publication number: 20030158208
    Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 10, 2003
    Publication date: August 21, 2003
    Applicant: Pfizer Inc.
    Inventors: Stevin H. Zorn, Mark A. Sanner, Antor F. Fliri, Patricia A. Seymour